Fiorentino, F., Canali, B., Morelli, P. and Demma, F. (2023) “Brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine for first-line treatment of stage IV HL: cost impact on subsequent lines in Italy”, AboutOpen, 10(1), pp. 6–12. doi: 10.33393/ao.2023.2486.